Insider Selling: Quantum-Si (NASDAQ:QSI) CEO Sells $10,857.60 in Stock

by · The Cerbat Gem

Quantum-Si Incorporated (NASDAQ:QSI – Get Free Report) CEO Jeffrey Alan Hawkins sold 11,310 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $0.96, for a total value of $10,857.60. Following the completion of the transaction, the chief executive officer owned 3,681,113 shares in the company, valued at approximately $3,533,868.48. The trade was a 0.31% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Jeffrey Alan Hawkins also recently made the following trade(s):

  • On Tuesday, June 23rd, Jeffrey Alan Hawkins sold 11,311 shares of Quantum-Si stock. The shares were sold at an average price of $0.90, for a total value of $10,179.90.
  • On Monday, April 20th, Jeffrey Alan Hawkins sold 83,712 shares of Quantum-Si stock. The shares were sold at an average price of $1.01, for a total value of $84,549.12.

Quantum-Si Price Performance

Shares of NASDAQ:QSI traded down $0.05 during trading on Wednesday, reaching $0.83. 5,042,480 shares of the stock were exchanged, compared to its average volume of 6,078,957. Quantum-Si Incorporated has a 1-year low of $0.69 and a 1-year high of $3.10. The stock has a fifty day moving average of $0.99 and a two-hundred day moving average of $1.04. The firm has a market cap of $180.13 million, a price-to-earnings ratio of -1.62 and a beta of 3.18.

Quantum-Si (NASDAQ:QSI – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.02. Quantum-Si had a negative return on equity of 47.35% and a negative net margin of 5,605.88%.The company had revenue of $0.26 million for the quarter, compared to analysts’ expectations of $0.30 million. Sell-side analysts forecast that Quantum-Si Incorporated will post -0.49 EPS for the current year.

Institutional Investors Weigh In On Quantum-Si

A number of hedge funds have recently made changes to their positions in QSI. JPMorgan Chase & Co. boosted its holdings in shares of Quantum-Si by 15.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 66,656 shares of the company’s stock worth $131,000 after buying an additional 9,005 shares during the last quarter. The Manufacturers Life Insurance Company raised its position in Quantum-Si by 27.4% in the second quarter. The Manufacturers Life Insurance Company now owns 49,082 shares of the company’s stock worth $96,000 after acquiring an additional 10,564 shares during the period. Prudential Financial Inc. bought a new stake in Quantum-Si in the second quarter worth about $25,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Quantum-Si by 23.8% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 70,552 shares of the company’s stock valued at $85,000 after acquiring an additional 13,546 shares during the last quarter. Finally, Cerity Partners LLC purchased a new position in Quantum-Si in the second quarter valued at about $29,000. 39.90% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Quantum-Si in a research report on Friday, March 27th. Canaccord Genuity Group cut their price target on Quantum-Si from $1.50 to $1.00 and set a “hold” rating for the company in a research note on Wednesday, March 4th. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Quantum-Si has an average rating of “Reduce” and a consensus target price of $1.00.

View Our Latest Analysis on QSI

Quantum-Si Company Profile

(Get Free Report)

Quantum-Si Inc is a life sciences instrumentation company headquartered in Guilford, Connecticut, developing next-generation proteomics solutions based on semiconductor sequencing technology. The company’s core offering centers on a proprietary single-molecule protein sequencing platform that uses a silicon-based sensor chip to convert protein data into digital signals. This approach is designed to deliver high sensitivity, single-amino-acid resolution and deep proteome coverage while potentially reducing cost and complexity compared to traditional mass spectrometry methods.

Quantum-Si’s product roadmap includes the development and commercialization of an integrated system comprising instruments, consumable reagents and proprietary data analysis software.

Recommended Stories